SCHEMBL16939

SCHEMBL16939

O=S(=O)(C1=CC=CCC1=S)N1CCNCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.41
ALDH1A1 P00352 3/20 0.40
USP2 O75604 1/20 0.38
PKM P14618 1/20 0.37
KMT2A Q03164 3/20 0.37
CYP3A4 P08684 4/20 0.33
NFKB1 P19838 3/20 0.33
CYP1A2 P05177 3/20 0.33
KDM4E B2RXH2 2/20 0.33
TP53 P04637 2/20 0.33
CYP2D6 P10635 2/20 0.33
MAPK1 P28482 2/20 0.33
MYLK Q15746 2/20 0.33
TSHR P16473 2/20 0.33
MEN1 O00255 1/20 0.33
CYP2C9 P11712 1/20 0.33
THPO P40225 1/20 0.33
HIF1A Q16665 1/20 0.33
LMNA P02545 2/20 0.33
CYP2C19 P33261 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL17111 0.98 ALDH1A1 (0.41) MAPTALDH1A1USP2PKMKMT2A
SCHEMBL17666 0.84 GFER (0.46) ALDH1A1PKMPOLBRAB9A
SCHEMBL12078539 0.81 CYP3A4 (0.40) CYP3A4NFKB1CYP2D6PRKD3PRKCG
Hydrochloric Acid SCHEMBL16218 0.80 CYP3A4 (0.40) CYP3A4NFKB1CYP2D6PRKD3PRKCG
SCHEMBL22891 0.76
SCHEMBL16420 0.72 CA1 (0.41) ALDH1A1KMT2ATSHRMEN1POLB
SCHEMBL10752804 0.72
SCHEMBL16812 0.71 GCKR (0.30)
SCHEMBL7341448 0.70
SCHEMBL1564281 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609081-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES Amgen Inc. (US) 2013-07-03 EP disclosed
WO-2012027261-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-03-01 WO disclosed